The Trump administration has abruptly halted HIV aid to South Africa, a move that global health experts warn could undo decades of progress in combating the epidemic. The decision, announced late on Tuesday, freezes billions of dollars in funding from the President's Emergency Plan for AIDS Relief (PEPFAR), which has been instrumental in providing antiretroviral treatment to millions of South Africans.
For the people of townships like Soweto and Khayelitsha, this is not a diplomatic squabble but a matter of life and death. Thandiwe Mokoena, a 34-year-old mother of two in Soweto, relies on free antiretroviral drugs provided by PEPFAR-funded clinics. "Without these medicines, I won't see my children grow up," she told me, her voice trembling. "They are our lifeline."
The funding freeze comes as part of a broader review of US foreign aid, with administration officials citing concerns about corruption and mismanagement in the South African health system. But critics argue the move is politically motivated, linked to tensions over South Africa's land reform policies and its close ties to Russia and China. The timing could not be worse. South Africa already struggles with one of the highest HIV burdens globally: 7.8 million people live with the virus, and 13 per cent of the population is infected. PEPFAR provides nearly 20 per cent of the country's HIV budget.
Dr. Lindiwe Zulu, a physician at a community clinic in Johannesburg, described the impact on her patients. "We have people who have been stable on treatment for years. Suddenly stopping funding means interrupting their therapy. That leads to drug resistance, higher viral loads, and increased transmission. It is a public health catastrophe in the making."
Community health workers, many of whom are women from the same townships they serve, now face an uncertain future. They earn modest stipends from PEPFAR to trace patients who miss appointments, deliver medicines, and provide counselling. "It is not just a job," says Nomsa Buthelezi, a peer educator in Durban. "It is a calling. But how can I help if the money dries up?"
The ripples extend far beyond South Africa. The country is a linchpin in global HIV research: trials for new drugs, vaccine development, and implementation science rely on its robust infrastructure. A funding freeze could stall breakthroughs that benefit millions worldwide. Moreover, the global health community fears a domino effect. Other nations may see US commitment wane, prompting cuts in their own HIV programmes. "This is not just about South Africa," said Dr. John Nkengasong, former head of the Africa Centres for Disease Control. "It undermines the entire global health security architecture."
South Africa's health minister, Dr. Zweli Mkhize, condemned the decision, calling it "a betrayal of shared humanity." He confirmed that the government would seek to fill the gap, but a stressed economy and rising debt make that a tall order. "We will not let our people die," he said, though he offered no timeline for replacement funding.
The White House has remained silent, but a State Department spokesperson hinted that funding could resume if South Africa addresses "serious concerns" over governance and alignment with US interests.
In the meantime, clinics brace for shortages. Pharmacies report that supplies of crucial antiretroviral drugs like tenofovir and dolutegravir will last only another eight weeks. Patients are already hoarding pills, and queues grow longer as people seek clarity. The human cost of this policy shift is not abstract. It is etched on the faces of mothers, fathers, and children who have clung to life through decades of struggle. The question now is whether international donors can step in before the damage is irreversible.
